Fifty-nine clinical-stage psychedelic drug stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances now trade on North American stock exchanges. The non-tradable munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index of 12 constituents with market capitalizations of $50M or more was up +8.9% last week albeit still down -18.5% YTD.

Eight of the constituents were up last week of which 6 did so by 5% or more while 2 of the remaining 4 were down in excess of 5%. The major winners and losers were as follows:

Major Winners 

1. Small Pharma (DMTTF): +147.8% last week and is now UP 58.3% since it began trading on June 3rd
   • announced its upgrade from the OTC Pink to the OTCQB  Venture Market effective last Wednesday
   • announced that it has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (DMT) assisted therapies for the treatment of major depressive disorder following discussions with the U.K. Medicines and Healthcare products Regulatory Agency.
2. Awakn (AWKNF): +23.5% but is still DOWN -8.3% since it began trading on June 23rd
   • announced that its Bristol Clinic - the UK's First Medical Psychedelic Clinic - has received Care Quality Commission approval to begin delivering ketamine-assisted psychotherapy treatments.
3. Compass (CMPS): +20.7% and is now UP +30.2% YTD
   • announced that it has been granted its fourth patent by the US Patent and Trademark Office covering its Form A hydrate psilocybin
   • shared an open-label study of psilocybin therapy for depression in cancer patients which administered a single does of its COMP360 psilocybin therapy, and found that after one week 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.
4. atai (ATAI): +13.0% but is still DOWN -21.6% since it began trading on June 18th
5. Red Light (TRUFF): +6.3% but is still DOWN -32% YTD

Major Losers

1. Mydecine (MYCOF): -10.7% last week and is now DOWN -40% YTD
2. GH Research (GHRS): -14.7% and is now DOWN -24.7% since it began trading on June 25th

Action Going Forward

You are encouraged to click on the hyperlinked symbols above of those stocks you are interest in and review their latest financial statements and commentary as found in the TalkMarkets data there.